Merck, Bristol-Myers Face India Patent Threats

Jan 21, 2014

Bloomberg

Drugmakers face threats to protecting their patents in India as a government-appointed panel prepares to evaluate more drugs in order to allow local firms to make low-priced generics.

Among the therapies the committee is preparing to study or had an early look at are two diabetes drugs, Merck’s sitagliptin medication, Januvia, and Bristol-Myers’ saxagliptin drug called Onglyza; Merck’s HIV drug raltegravir, sold under the brand name Isentress; and Bristol-Myers’ arthritis drug abatacept, sold as Orencia, according to Bloomberg sources.

Read the Bloomberg press release

 

Join the discussion

We welcome your thoughtful comments. Please comply with our Community rules.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments